Mesoblast Limited (MESO): Price and Financial Metrics

Mesoblast Limited (MESO)

Today's Latest Price: $14.93 USD

0.35 (-2.29%)

Updated Nov 27 1:00pm

Add MESO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MESO Stock Summary

  • Mesoblast Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 10.48% of US listed stocks.
  • Of note is the ratio of Mesoblast Ltd's sales and general administrative expense to its total operating expenses; merely 11.98% of US stocks have a lower such ratio.
  • MESO's price/sales ratio is 108.73; that's higher than the P/S ratio of 97.08% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Mesoblast Ltd are AUMN, PZG, AKER, NOVN, and NEU.
  • Visit MESO's SEC page to see the company's official filings. To visit the company's web site, go to

MESO Stock Price Chart Interactive Chart >

Price chart for MESO

MESO Price/Volume Stats

Current price $14.93 52-week high $21.28
Prev. close $15.28 52-week low $3.12
Day low $14.81 Volume 240,800
Day high $15.38 Avg. volume 789,995
50-day MA $13.22 Dividend yield N/A
200-day MA $11.80 Market Cap 1.75B

Mesoblast Limited (MESO) Company Bio

Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.

MESO Latest News Stream

Event/Time News Detail
Loading, please wait...

MESO Latest Social Stream

Loading social stream, please wait...

View Full MESO Social Stream

Latest MESO News From Around the Web

Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.

Mesoblast plunges on FDA recommendation of additional study for remestemcel-L in SR-aGVHD

The FDA has issued a Complete Response Letter to Mesoblast's (MESO) Biologics License Application ((BLA)) for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).While the Oncologic Drugs Advisory Committee of the FDA voted 9:1 that the available data support the efficacy of remestemcel-L in pediatric...

Seeking Alpha | October 2, 2020

The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates

Biotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: JNJ ) kickstarting a Phase 3 trial of its coronavirus vaccine candidate. A few clinical readouts released during the week triggered strong moves. Vaccinex Inc (NASDAQ: VCNX ) and AC Immune SA (NASDAQ: ACIU ) were among the worst decliners of the week, with the former reacting to a failed mid-stage trial of lead drug in Huntington's disease, while the latter plunged after an out-licensed Alzheimer's drug flunked a mid-stage trial. Here are the key catalysts for the unfolding week. Conferences World Muscle Society, or WMS, 25: Virtual Congress: Sept. 28-Oct. 2 Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, meeting: Sept. 30- Oct. ...

Benzinga | September 26, 2020

Mesoblast (ASX:MSB) wins Biotech award for Remestemcel-L

15 Sep 2020 - Mesoblast (ASX:MSB), today announced that its lead product candidate remestemcel-L has been selected as the winner of the Fierce Innovation Awards - Life Sciences Edition 2020 for Biotech Innovation.

Finance News Network | September 14, 2020

Late-stage study of Mesoblast cell therapy in COVID-19 to continue as is

The independent Data Safety Monitoring Board has completed its first interim analysis of data from a Phase 3 clinical trial evaluating Mesoblast Limited's ([[MESO]] -0.3%) remestemcel-L, an allogeneic mesenchymal stem cell product derived from bone marrow, in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome ((ARDS)).Based on preliminary results from...

Seeking Alpha | September 4, 2020

Mesoblast's (ASX:MSB) good COVID-19 news | Rask Media

Mesoblast Limited (ASX:MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients.

Rask Media | September 4, 2020

Read More 'MESO' Stories Here

MESO Price Returns

1-mo 43.28%
3-mo -22.80%
6-mo 16.37%
1-year 135.12%
3-year 202.23%
5-year 118.91%
YTD 102.58%
2019 78.88%
2018 -29.45%
2017 9.16%
2016 -15.88%
2015 -64.19%

Continue Researching MESO

Here are a few links from around the web to help you further your research on Mesoblast Ltd's stock as an investment opportunity:

Mesoblast Ltd (MESO) Stock Price | Nasdaq
Mesoblast Ltd (MESO) Stock Quote, History and News - Yahoo Finance
Mesoblast Ltd (MESO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8112 seconds.